Cited by 377SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

Open access

Ali, Kashif, Berman, Gary, Zhou, Honghong, Deng, Weiping, Faughnan, Veronica, Coronado-Voges, Maria, Ding, Baoyu, Dooley, Jacqueline, Girard, Bethany, Hillebrand, William, Pajon, Rolando, Miller, Jacqueline M., Leav, Brett, McPhee, Roderick·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2109522PMC PMC8385554

Open this paper in CoChat — free account

Abstract

BACKGROUND: The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents are unknown. METHODS: In this ongoing phase 2-3, placebo-controlled trial, we randomly assigned healthy adolescents (12 to 17 years of age) in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine (100 μg in each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of mRNA-1273 in adolescents and the noninferiority of the immune response in adolescents as compared with that in young adults (18 to 25 years of age) in a phase 3 trial. Secondary objectives included the efficacy of mRNA-1273 in preventing Covid-19 or asymptomatic severe acute respiratory syndrome coronavirus 2 infection. RESULTS: A total of 3732 participants were randomly assigned to receive mRNA-1273 (2489 participants) or placebo (1243 participants). In the mRNA-1273 group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 93.1% and 92.4%, respectively), headache (in 44.6% and 70.2%, respectively), and fatigue (in 47.9% and 67.8%, respectively); in the placebo group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 34.8% or 30.3%, respectively), headache (in 38.5% and 30.2%, respectively), and fatigue (in 36.6% and 28.9%, respectively). No serious adverse events related to mRNA-1273 or placebo were noted. The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08 (95% confidence interval [CI], 0.94 to 1.24), and the absolute difference in serologic response was 0.2 percentage points (95% CI, -1.8 to 2.4), which met the noninferiority criterion. No cases of Covid-19 with an onset of 14 days after the second injection were reported in the mRNA-1273 group, and four cases occurred in the placebo group. CONCLUSIONS: The mRNA-1273 vaccine had an acceptable safety profile in adolescents. The immune response was similar to that in young adults, and the vaccine was efficacious in preventing Covid-19. (Funded by Moderna and the Biomedical Advanced Research and Development Authority; Teen COVE ClinicalTrials.gov number, NCT04649151.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2109522

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H. P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,774
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Family violence and COVID‐19: Increased vulnerability and reduced options for support
Usher, K., Bhullar, N., Durkin, J., Gyamfi, N., & Jackson, D. (2020) · International Journal of Mental Health Nursing · doi:10.1111/inm.12735 · Cited by 979
Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults
Viner, R., Mytton, O. T., Bonell, C. P., Meléndez‐Torres, G. J., Ward, J., Hudson, L. D., Waddington, C. S., Thomas, J., Russell, S., van der Klis, F. R. M., et al. (2020) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2020.4573 · Cited by 893
Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents
Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B., Senders, S., Bailey, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107456 · Cited by 889
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103916 · Cited by 673
Self-citation
Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020
Kim, L., WHITAKER, M. D., O’Halloran, A. C., Kambhampati, A. K., Chai, S. J., Reingold, A. L., Armistead, I., Kawasaki, B., Meek, J. I., Yousey-Hindes, K. M., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6932e3 · Cited by 513

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 1

10.1056/NEJMoa2027906 · DOI · Paper page

Sorted by citations

Items 201–300 of 374

RETRACTED ARTICLE: Long-Term Safety Analysis of the BBV152 Coronavirus Vaccine in Adolescents and Adults: Findings from a 1-Year Prospective Study in North India
Kaur, U., Jaiswal, A., Jaiswal, A., Singh, K., Pandey, A., Chauhan, M., Rai, M., Kansal, S., Patwardhan, K., Jaisawal, V., et al. (2024) · Drug Safety · doi:10.1007/s40264-024-01432-6 · Cited by 6
Retracted
COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials
Mohammadi, S., Sisay, M. M., Saraswati, P. W., Osman, A. K., Zuithoff, N. P. A., Weibel, D. M., Sturkenboom, M., & Ahmadizar, F. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127342 · Cited by 8
COVID-19 in children: epidemic issues and candidate vaccines
Zhang, P., Wei, M., Jing, P., Li, Z., Li, J., & Zhu, F. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002169 · Cited by 10
Liver injury and cytopenia after BNT162b2 COVID‐19 vaccination in an adolescent
Kawasaki, Y., Matsubara, K., Hori, M., & ISOME, K. (2022) · Pediatrics International · doi:10.1111/ped.15178 · Cited by 6
Answers to common questions about COVID‐19 vaccines in children with cancer
Caniza, M. A., Homsi, M. R., Bate, J. M., Adrizain, R., Ahmed, T., Alexander, S. W., Bhattacharyya, A., Copado-Gutiérrez, J. L., Gutiérrez-Tobar, I. F., Lim, Y. Y., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29985 · Cited by 6
COVID-19 Vaccination in Pediatrics: Was It Valuable and Successful?
Raslan, M. A., Raslan, S. A., Shehata, E. M., Mahmoud, A. S., Sabri, N. A., Alzahrani, K. J., Alzahrani, F. M., Alshammeri, S., Azevedo, V., Lundstrom, K. H., et al. (2023) · Vaccines · doi:10.3390/vaccines11020214 · Cited by 7
Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus
Piyaphanee, N., Charuvanij, S., Thepveera, S., Toh, Z. Q., Licciardi, P. V., Pattaragarn, A., Wongprompitak, P., Boonnak, K., Pheerapanyawaranun, C., & Chokephaibulkit, K. (2024) · Lupus · doi:10.1177/09612033241232576 · Cited by 6
COVID‐19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non‐malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement
Furlong, E., Kotecha, R. S., Conyers, R. K., O'Brien, T. A., Hansford, J. R., Super, L., Downie, P., Eisenstat, D. D., Haeusler, G. M., McMullan, B. J., et al. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51444 · Cited by 5
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trialPreprint
Liu, L. T.-C., Chiu, C., Chiu, N., Tan, B., Lin, C., Cheng, H., Lin, M., Lien, C.-E., Chen, C., & Huang, L. (2022) · medRxiv · doi:10.1101/2022.03.14.22272325 · Cited by 6
Adverse events following SARS-CoV-2 mRNA vaccination in norwegian adolescents
Larsen, V. B., Gunnes, N., Gran, J. M., Dahl, J., Bøås, H., Watle, S. V., Berild, J. D., Greve‐Isdahl, M., Størdal, K., Gulseth, H. L., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45261-2 · Cited by 7
Antigen-specific T cell responses in SARS-CoV-2 mRNA-vaccinated children
Philpott, J. D., Miller, J. D., Boribong, B. P., Charles, S., Davis, J. P., Kazimierczyk, S., Jimena, B., Leonard, M. M., Shreffler, W. G., Fasano, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101298 · Cited by 8
Self-citation
Immunostimulatory/Immunodynamic model of mRNA ‐1273 to guide pediatric vaccine dose selection
Ivaturi, V. D., Attarwala, H. Z., Deng, W., Ding, B., Ghamloush, S. S., Girard, B., Iqbal, J., Minnikanti, S., Zhou, H., Miller, J. M., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13237 · Cited by 5
Self-citation
Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis
Rai, S., & Tripathi, S. S. (2025) · The Indian Journal of Medical Research · doi:10.25259/ijmr_750_2024 · Cited by 5
The COVID-19 pandemic in children and young people during 2022–24: what new did we learn?
Rudan, I., Kerr, S., Simpson, C. R., Kurdi, A. B., Adeloye, D., Robertson, C., & Sheikh, A. (2025) · Journal of Global Health · doi:10.7189/jogh.15.01002 · Cited by 6
A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme
Goh, F. T., Chew, Y. Z., Tam, C. C., Yung, C. F., & Clapham, H. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100581 · Cited by 5
Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults
Sun, T., Li, L., Mues, K. E., Georgieva, M. V., Kirk, B., Mansi, J. A., de Velde, N. V., & Beck, E. C. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01005-1 · Cited by 6
Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
Akamine, C. M., & Sahly, H. M. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.007 · Cited by 5
Responsiveness to second and third dose of mRNA COVID‐19 vaccination in adolescent and young adult heart transplant recipients
Feingold, B., Berman, P., Moninger, A., Huston, A., Stinner, B., West, S. C., Rose‐Felker, K., Zinn, M. D., Miller, S. A., & Michaels, M. G. (2022) · Pediatric Transplantation · doi:10.1111/petr.14272 · Cited by 4
Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 Vaccines Against Hospitalisations Among Children and Adolescents During the Omicron Outbreak in ArgentinaPreprint
González, S. E., Olszevicki, S., Gaiano, A., Varela, A. N., Regairaz, L., Salazar, M. R., Pesci, S. A., Marín, L., González, V., Varela, T., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4087375 · Cited by 5
Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review
Weber, D. J., Zimmerman, K. O., Tartof, S. Y., McLaughlin, J. M., & Pather, S. (2024) · Vaccines · doi:10.3390/vaccines12090989 · Cited by 4
Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines
Sohn, W. Y., Goody, S. M. G., Reid, D. W., Edwards, D. K., Urdaneta, V., Doyle, B. P., Straus, W. L., Henry, C., & Rizkalla, B. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128394 · Cited by 4
ATAGI Targeted Review 2021: the national COVID-19 vaccination program
Jayasinghe, S. H., Patel, C., Armstrong, L., Chiu, C., Macartney, K. K., Flanagan, K. L., Gibney, K. B., Giles, M., Crawford, N. W., Cheng, A., et al. (2023) · Communicable Diseases Intelligence · doi:10.33321/cdi.2023.47.20 · Cited by 3
Clinical trials of pharmacological interventions for SARS‐CoV‐2 published in leading medical journals report adherence but not how it was assessed
Lee, C., Otunla, A. A., Brennan, I., Aronson, J. K., & Nunan, D. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15992 · Cited by 4
Comparing the Efficacy and Adverse Events of Available COVID-19 Vaccines Through Randomized Controlled Trials: Updated Systematic Review and Network Meta-analysis
Hossaini, S., Keramat, F., Cheraghi, Z., Zareie, B., & Doosti‐Irani, A. (2023) · Journal of Research in Health Sciences · doi:10.34172/jrhs.2023.128 · Cited by 5
The Assessment of Anti–SARS‐CoV‐2 Antibodies in Different Vaccine Platforms: A Systematic Review and Meta‐Analysis of COVID‐19 Vaccine Clinical Trial Studies
Mirzakhani, M., Bayat, M., Dashti, M., Tahmasebi, S., Rostamtabar, M., Ghaleh, H. E. G., & Amani, J. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2579 · Cited by 5
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
Figueroa, A. L., Ali, K., Berman, G., Xu, W., Deng, W., Girard, B., Yeakey, A. M., Slobod, K., Miller, J. M., Das, R., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2436714 · Cited by 3
Self-citation
Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial
Deming, M. E., Brown, E. R., McArthur, M. A., Schrag, S. J., Arvay, M. L., Humphrys, M. S., Ravel, J., Adelglass, J. M., Essink, B. J., Musante, D. B., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.100984 · Cited by 4
Proposals to Accelerate Novel Vaccine Development for Children
Permar, S. R., Creech, C. B., Edwards, K. M., & Walter, E. B. (2021) · PEDIATRICS · doi:10.1542/peds.2021-054593 · Cited by 4
mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273
Dowell, A. C., Powell, A. A., Davis, C., Scott, S., Logan, N. A., Willett, B. J., Bruton, R. K., Ayodele, M., Jinks, E., Gunn, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882515 · Cited by 5
Impact of Coronavirus Disease of 2019 Vaccine on Health and Physical Activities Among Physical Education Students in China
Laar, R. A., Zhang, Z., Menhas, R., Zhang, L., Zhu, S., Fan, X., Wang, W., & Li, S. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.889311 · Cited by 4
COVID ‐19: The disease, the vaccine and the heart
Turner, C. (2023) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.16407 · Cited by 4
Current status of COVID-19 vaccination: safety and liability concern for children, pregnant and lactating women
Das, S. K., Paul, M., Behera, B. C., & Thatoi, H. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2056025 · Cited by 4
Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in childrenPreprint
Puga-Gómez, R., Ricardo-Delgado, Y., Iriarte, C. R., Céspedes-Henriquez, L., Piedra-Bello, M., Mendoza, D. L. V., Pérez, N. P., Paredes-Moreno, B., Rodríguez-González, M., Valenzuela‐Silva, C., et al. (2022) · medRxiv · doi:10.1101/2022.03.03.22271313 · Cited by 4
Impact and Effectiveness of COVID ‐19 mRNA Vaccination Against COVID ‐19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain
Castillo‐Cano, B., Riefolo, F., Villalobos, F., Martín‐Pérez, M., Messina, D., Elbers, R., Brink‐Kwakkel, D., Bissacco, C. A., Segundo, E., Saiz, L. C., et al. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70239 · Cited by 3
A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines
Bausch-Jurken, M. T., Dawson, R. S., Ceddia, F., Urdaneta, V., Marks, M. A., & Doi, Y. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2402955 · Cited by 3
Analysing transcriptomic signatures and identifying potential genes for the protective effect of inactivated COVID-19 vaccines
Chen, H.-Q., Zhang, L., Xu, C., Shen, X.-Y., Lou, J., & Wu, S. (2023) · PeerJ · doi:10.7717/peerj.15155 · Cited by 4
Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT
Leung, D., Duque, J. S. R., Tu, W., & Lau, Y. (2023) · Pediatric Discovery · doi:10.1002/pdi3.8 · Cited by 3
A Critical Assessment of COVID-19 Genomic Vaccines
Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 4
Clinical Syndromes Related to SARS-CoV-2 Infection and Vaccination in Pediatric Age: A Narrative Review
Mastrolia, M. V., Cillia, C. D., Orlandi, M., Abu‐Rumeileh, S., Maccora, I., Maniscalco, V., Marrani, E., Pagnini, I., & Simonini, G. (2023) · Medicina · doi:10.3390/medicina59112027 · Cited by 5
Novel Inhibitory Role of Fenofibric Acid by Targeting Cryptic Site on the RBD of SARS-CoV-2
Huang, J., Chan, C., & Zhou, R. (2023) · Biomolecules · doi:10.3390/biom13020359 · Cited by 3
Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar
Osman, K., Mundodan, J. M., Chowdhury, J., Ravi, R. P., Baaboura, R., Albuquerque, J., Riaz, B., Emran, R. Y., Batoul, K., Esameldin, A. M., et al. (2023) · Vaccines · doi:10.3390/vaccines11101522 · Cited by 2
Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms
Gohda, E. (2022) · Journal of Disaster Research · doi:10.20965/jdr.2022.p0007 · Cited by 3
Partial or Full Doses First? Vaccine Allocation Under Limited SupplyPreprint
Hu, M., Zhang, C., & Zhou, Y. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4411818 · Cited by 3
Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in ChildrenPreprint
Dixit, A., Bennett, R., Ali, K., Griffin, C., Clifford, R. A., Turner, M. A., Poston, R., Hautzinger, K., Yeakey, A. M., Girard, B., et al. (2023) · medRxiv · doi:10.1101/2023.06.23.23291767 · Cited by 3
Self-citation
Efficacy and Safety of COVID-19 Vaccines in Adolescents: Systematic Review of Randomized Controlled Studies and Observational Studies
Choi, S., Yu, S., Kim, J., Choi, M., Choi, Y. Y., Choi, J. H., Yun, K. W., & Choe, Y. J. (2024) · Pediatric Infection & Vaccine · doi:10.14776/piv.2024.31.e16 · Cited by 3
BNT162b2 COVID-19 vaccination uptake, safety, effectiveness, and waning in children and young people aged 5–11 years in Scotland
Rudan, I., Kerr, S., Sullivan, C., Jeffrey, K., Grange, Z., Fenton, L., Kurdi, A. B., Shi, T., Cullen, L. A., Simpson, C. R., et al. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04250 · Cited by 3
Nanocarrier-based immunotherapy for viral diseases
Liu, D., Zhao, T., Li, Y., Huang, L., Che, J., Zou, P., Yang, W., Ding, J., Wu, P., Gao, X., et al. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100408 · Cited by 2
SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study
Brugha, R. E., Kirkham, A. J., Bate, J. M., Burke, G. A. A., Hughes, A. I., Magwaro, S., Pope, A., Beesley, R. P., Lax, S., Kelly, E., et al. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114873 · Cited by 2
Polymeric particle-based antigen delivery system: From immunological engineering to clinical translation
Shi, Y., Zhu, L., Qiao, Z., Zhai, Y., Di, J., Wang, S., Cui, J., Wang, Y., Ran, Y., & Gao, J. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100466 · Cited by 2
From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine
Straus, W. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2653369 · Cited by 3
The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists
Visser, C., Yousefi, A., Nierman, M. C., Huisman, M. V., Gulpen, A. J. W., van Ommen, C. H., & Kruip, M. J. H. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.005 · Cited by 2
Attitudes Toward COVID-19 Vaccination Among Occupational Therapy Professionals and Students in Early 2021
Cage, S. A., Warner, B. J., Gallegos, D. M., Cage, H., & Brown, D. (2022) · Internet Journal of Allied Health Sciences and Practice · doi:10.46743/1540-580x/2022.2180 · Cited by 2
Comparison of Salivary Secretion, pH, and Buffer Capacity Between COVID-19 Vaccinated and Unvaccinated Child Patients Visiting Dental Clinics of University Hospitals in Riyadh City, Saudi Arabia
Alenazi, H., Baseer, M. A., AlMugeiren, O. M., & Ingle, N. A. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s437563 · Cited by 2
Adenomesenteritis following SARS-CoV-2 Vaccination in Children: A Case Report and Review of The Literature
Bloise, S., Marcellino, A., Martucci, V., Sanseviero, M., Testa, A., Giudice, E. D., Spatuzzo, M., Sermoneta, D., Ventriglia, F., & Lubrano, R. (2022) · Children · doi:10.3390/children9070993 · Cited by 2
Monoclonal antibodies for the treatment of COVID-19 infection in children
Ling, K. M., & Dougan, M. L. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2134117 · Cited by 2
Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial
Figueroa, A. L., Torres, D., Reyes-Acuna, C., Matherne, P. G., Yeakey, A. M., Deng, W., Xu, W., Sigal, Y., Chambers, G., Olsen, M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00501-2 · Cited by 2
Self-citation
Clinical trials of Covid vaccines in adolescents: do the EMA and FDA have access to the same data?Preprint
Banoun, H. (2021) · doi:10.32388/kp77nw · Cited by 1
Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialPreprint
Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988003 · Cited by 2
Self-citation
Immunostimulatory/immunodynamic model of mRNA-1273 to guide pediatric vaccine dose selectionPreprint
Attarwala, H. Z., Deng, W., Ding, B., Ghamloush, S. S., Girard, B., Iqbal, J., Ivaturi, V. D., Minnikanti, S., Zhou, H., Miller, J. M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3317875/v1 · Cited by 2
Self-citation
Adverse Events Following SARS-CoV-2 mRNA Vaccination in Adolescents: A Norwegian Nationwide Register-Based StudyPreprint
Larsen, V. B., Gunnes, N., Gran, J. M., Dahl, J., Bøås, H., Watle, S. V., Berild, J. D., Greve‐Isdahl, M., Størdal, K., Gulseth, H. L., et al. (2023) · medRxiv · doi:10.1101/2023.12.13.23299926 · Cited by 2
Vacunación contra COVID-19 en niños
Aragón-Nogales, R., & Miranda-Novales, M. G. (2021) · Revista Mexicana de Pediatría · doi:10.35366/102187 · Cited by 2
Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials
Soegiarto, G., Fajar, J. K., Wulandari, L., Anshory, M., Ilmawan, M., Asmiragani, A., Illiyana, H., Adam, A., Lamadi, S., Sa'adah, U., et al. (2022) · F1000Research · doi:10.12688/f1000research.110281.1 · Cited by 1
Children Lagging with COVID-19 Vaccination
Noor, A., Bäcker, M., & Krilov, L. R. (2022) · Pediatric Annals · doi:10.3928/19382359-20220314-06 · Cited by 1
Safety of the BNT162b2 mRNA COVID-19 vaccine in children and adolescents with juvenile idiopathic arthritis: a tertiary-center early experience
Abdelgalil, A. A., Bakry, R., & Muzaffer, M. A. (2022) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-022-00143-z · Cited by 1
Pediatric cancer care management during the COVID-19 pandemic: a review of the literature and a single-centre real-life experience of an Italian pediatric oncology unit
Nigro, O., Oltolini, C., Barzaghi, F., Uberti‐Foppa, C., Cicalese, M. P., Massimino, M., & Schiavello, E. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2245148 · Cited by 1
Anti-SARS-CoV-2 Vaccination and PIMS-TS—Friends or Foe? Case Reports and Literature Review
Opoka‐Winiarska, V., Morawska, I., Mertowska, P., Gosik, K., Kądziołka, O., & Grywalska, E. (2024) · Vaccines · doi:10.3390/vaccines12030278 · Cited by 1
Adverse events of COVID-19 vaccination during 2021–2022 suppressed by breakfast consumption and favorable sleeping habit among Japanese university students
Tetsuka, N., Suzuki, K., Suzuki, K., Ishihara, T., Miwa, T., Tajirika, S., Adachi, M., Horita, R., Fukao, T., & Yamamoto, M. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100516 · Cited by 1
The development of therapeutics and vaccines against COVID-19.
Zhao, T., Wang, Z., Tong, M., & Fei, Y. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116643 · Cited by 1
COVID-19 vaccination: challenges in the pediatric population
Azoicai, A. N., Miron, I. C., Lupu, A., Alexoae, M. M., Stârcea, I. M., Alecsa, M., Lupu, V. V., Danielescu, C., Nedelcu, A. H., Șalaru, D. L., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1390951 · Cited by 1
Serious Adverse Drug Reactions to COVID-19 Vaccines in the Pediatric Population: A Retrospective, Cross-Sectional Study Utilizing the Eudravigilance Database for the European Economic Area
Nazar, G., Olszlegier, J., Kamińska, A., Plata‐Nazar, K., & Nazar, W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186542 · Cited by 1
An immunoinformatics approach to study the physicochemical properties and efficacy of mRNA-1273 against SARS-CoV-2
Srivastava, R. (2026) · Next research. · doi:10.1016/j.nexres.2026.102118 · Cited by 1
Adverse reactions to coronavirus disease 2019 vaccines in children and adolescents
Lee, E., Kim, K., Kim, M., Yang, H., Yum, H. Y., Lee, M.-H., & Lee, Y. J. (2022) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2022.10.1.9 · Cited by 1
Corbevax Vaccine Side Effects in Children of Age Group 12–14 Years: A Prospective Observational Study
Pushkar, K., Bobdey, S., Kotoki, R., Koundinya, K., Michael, P., & Kaushik, S. K. (2023) · Journal of Marine Medical Society · doi:10.4103/jmms.jmms_135_22 · Cited by 1
Comparison of the Onset and End of Specific and Major Side Effects in Iranian Teenage Participants Vaccinated With COVID-19 Vaccine: Sinopharm and Soberana
Tavakoli, N., Nafissi, N., Shokri, S., Fallahpour, M., Soleimani, S., Riahi, T., Kalantari, S., Goodarzi, A., & Valizadeh, R. (2023) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.37.15 · Cited by 1
The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia
Kovačić, B., Pavičić, M., Skvrce, N. M., & Tomić, S. (2023) · Acta Pharmaceutica · doi:10.2478/acph-2023-0029 · Cited by 1
Comprehensive Review of the Initial 11 WHO Emergency Use Listed COVID-19 Vaccine Candidates: Mechanisms, Efficacy, and Comparative Attributes for Safety and Well-Being
Aditi, K., Kumari, N., Singh, P., Kumari, A., Deen, S. Y., & Kumar, R. (2023) · Microsphere · doi:10.59118/vqar2242 · Cited by 1
Effect of Platform Type on Clinical Efficacy of SARS-CoV-2 Vaccines in Prime Vaccination Settings: A Systematic Review and Meta-Regression of Randomized Controlled Trials
Goryaynov, S. V., & Gurova, O. Y. (2024) · Vaccines · doi:10.3390/vaccines12020130 · Cited by 1
Self-reported Side Effects of SARS-CoV-2 Vaccination
Finsterer, J., & Hertz, D. (2023) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2024.10 · Cited by 1
Efficacy, Effectiveness, and Safety of COVID-19 Vaccine Compared to Placebo in Preventing COVID-19 Infection among 12-17 Years Old: A Systematic Review
Gregorio, G. V., Catacutan, A. M. B., Perez, M. L. M., & Dans, L. F. (2024) · Acta Medica Philippina · doi:10.47895/amp.v58i7.7930 · Cited by 1
COVID-19 Vaccines in the Pediatric Population: A Focus on Cardiac Patients
Lababidi, G. H., Lababidi, H., Bitar, F. F., & Arabi, M. T. (2024) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2024/2667033 · Cited by 1
SARS-CoV-2 parental vaccination and risk of multisystem inflammatory syndrome in children: a single-center retrospective study
Falsaperla, R., Sortino, V., Collotta, A. D., Grassi, P., Vaccalluzzo, M. S., Pulvirenti, A., Gambilonghi, F., & Ruggieri, M. (2024) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2024.13.3.225 · Cited by 1
COVID-19 immunisation strategies for adolescents
Wang, W., & Zhu, F. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00563-2 · Cited by 1
Adverse effects of COVID-19 vaccine in the paediatric population: a focus on the cardiovascular system
Lababidi, G. H., Lababidi, H., Bitar, F. F., & Arabi, M. T. (2024) · Cardiology in the Young · doi:10.1017/s1047951124026118 · Cited by 1
Molecular approaches based on investigating the therapeutic benefits of Moringa oleifera: Insights into biochemical and spermatological and metabolites studies
Sankar, S. H. H., Umavathi, S., Gayathiri, E., & Prakash, P. (2025) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2025.100065 · Cited by 1
Clinical features and acute management of COVID-19 in children
Longbottom, K., Whittaker, E., & Penner, J. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10024320 · Cited by 1
Criteria for judging the immune markers of COVID‐19 disease vaccines
Lin, N., Fu, H., Pu, D., Quan, Y., Li, Y., Yin, X., Wei, Y., Wang, H., Ma, X., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.109
SARS-CoV-2-fertőzés és annak megelőzése gyermekkori krónikus szisztémás autoimmun betegségekben
Constantin, T., Kulcsár, A., Krivácsy, P., Mészner, Z., Ponyi, A., Tóth, A., Ónozó, B., & Szekanecz, Z. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32448 · Cited by 1
COVID-19 vaccination in patients with rheumatic diseases — status February 2022
Opoka‐Winiarska, V., & Smolewska, E. B. (2022) · Rheumatology Forum · doi:10.5603/fr.2021.0020 · Cited by 1
Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India
Inder, D., Manak, S., Akram, M. F., & Kumar, P. (2022) · Saudi Journal for Health Sciences · doi:10.4103/sjhs.sjhs_42_22 · Cited by 1
Real Life Evidence From the Use of COVID-19 mRNA Vaccines in Pediatric Populations
Lagousi, T., Tsagkli, P., & Spoulou, V. I. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003707 · Cited by 1
An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines
García, G. I., Rodríguez, Á. D., Fernández, B. D., Estrada, C. C., Ferreiro, T. G., García, N. C., & Seco‐Calvo, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247534 · Cited by 1
Efficacy and Safety of COVID-19 Vaccines in Different Variants and Doses: A Systematic Review
Delam, H., Moghaddam, S., & Zare, R. (2022) · Epidemiology and Health System Journal · doi:10.34172/ehsj.2022.33 · Cited by 1
Retrospective View of COVID-19 Pandemic: Treatment, Management and Development of Preventive Measures
Tym, P., Bayey, E., Brittain, A., Huang, A., Nandagopal, V., Singh, A., Scarlett, C., & CY, C. B. W. (2023) · Reports on Global Health Research · doi:10.29011/2690-9480.100158
Teen COVE study finds Moderna COVID-19 vaccine safe in adolescents
(2021) · Reactions Weekly · doi:10.1007/s40278-021-01222-0 · Cited by 1
Understanding differences in vaccination uptake among OECD countries
Turner, D., Woloszko, N., Chalaux, T., & Dek, M. (2022) · OECD Economics Department working papers · doi:10.1787/76482043-en · Cited by 3
Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents A Systematic Review and Meta-AnalysisPreprint
Hoffmann, S. S., Nielsen, S., Thysen, S. M., Duriseti, R. S., & Benn, C. S. (2023) · medRxiv · doi:10.1101/2023.12.07.23298573 · Cited by 1
Real-World Effectiveness of a Third Dose of mRNA-1273 versus BNT162b2 on Inpatient and Medically Attended COVID-19 among Immunocompromised Adults in the United StatesPreprint
Sun, T., Li, L., Mues, K. E., Georgieva, M. V., Kirk, B., Mansi, J. A., de Velde, N. V., & Beck, E. C. (2024) · medRxiv · doi:10.1101/2024.01.30.24302015 · Cited by 1
COVID-19 Vaccine Safety Studies among Vulnerable Populations: A Systematic Review and Meta-analysis of 120 Observational Studies and Randomized Clinical TrialsPreprint
Mohammadi, S., Sisay, M. M., Saraswati, P. W., Osman, A. K., Zuithoff, N. P. A., Weibel, D. M., Sturkenboom, M., & Ahmadizar, F. (2024) · medRxiv · doi:10.1101/2024.12.27.24319417 · Cited by 1
Association between Covid-19 BNT162b2 vaccination or SARS-CoV-2 infection and immune mediated diseases in 5 million 5-to-19-year-olds in four Nordic countriesPreprint
Tapia, G., Ljung, R., Thiesson, E. M., Pihlström, N., Nieminen, T. A., Bakken, I. J., Gulseth, H. L., Nohynek, H., Karlstad, Ø., & Hviid, A. P. (2025) · medRxiv · doi:10.1101/2025.03.09.25323620 · Cited by 1
„Coronavirus disease 2019 (COVID‑19)“ im Kindes- und Jugendalter
Zepp, F., & Knuf, M. (2021) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-021-01326-2 · Cited by 8

Authors: Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., Pajon, R., Miller, J. M., Leav, B., & McPhee, R.
Affiliations: From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).
Corresponding author: McPhee, Roderick
ORCID: Girard, Bethany
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-12-09
Volume: 385
Issue: 24
Pages: 2241-2251
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2109522
PMC: PMC8385554
OpenAlex: W3189261358
Cited by: 377
References: 20
Citations by year: 2026: 12 · 2025: 29 · 2024: 54 · 2023: 87 · 2022: 160 · 2021: 35
FWCI: 26.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, adolescents, vaccine safety, immunogenicity, neutralizing antibodies, non-inferiority, vaccine efficacy, asymptomatic infection, adverse events, serological response, pseudovirus neutralization assay, Omicron variant, Omicron BA.1
MeSH terms: Immunogenicity, Vaccine, COVID-19, Vaccine Efficacy, 2019-nCoV Vaccine mRNA-1273, Adolescent, Antibodies, Viral, Child, Female, Humans, Male, Single-Blind Method, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks